WHIM Syndrome Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | X4 Pharmaceuticals, NIAID

WHIM Syndrome Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | X4 Pharmaceuticals, NIAID
The WHIM Syndrome Market Forecast report offers an in-depth understanding of the WHIM Syndrome, historical and forecasted epidemiology as well as the WHIM Syndrome market trends in the 7MM.

DelveInsight’s “WHIM Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the WHIM Syndrome, historical and forecasted epidemiology as well as the WHIM Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.


To Know in detail about the WHIM Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; WHIM Syndrome Market Forecast


Some of the key facts of the WHIM Syndrome Market Report: 

  • The WHIM Syndrome market size was valued approximately USD 6.1 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In April 2024, X4 Pharmaceuticals announced that the FDA has granted approval for mavorixafor (Xolremdi) to treat WHIM syndrome in patients aged 12 and above. This marks the first approved therapy specifically designed for this rare inherited immunodeficiency disorder.

  • In 2022, the United States had the highest number of prevalent cases of WHIM Syndrome, with approximately 117 cases, while Spain had the lowest, with around 2 cases.

  • In 2022, around 47 males and 70 females in the United States were impacted by WHIM Syndrome. It’s projected that the prevalence of the condition will rise by 2032.

  • In 2022, France had the highest diagnosed prevalent cases of WHIM Syndrome among EU4 countries and the UK, with approximately 17 cases.

  • In 2022, there were 22 diagnosed prevalent cases of WHIM syndrome among individuals aged 18 years and older in the EU4 and the UK. It is anticipated that these cases will rise by 2032.

  • Key WHIM Syndrome Companies: X4 Pharmaceuticals, NIAID, and others

  • Key WHIM Syndrome Therapies: Mavorixafor, Plerixafor, X4P-001, and others

  • The WHIM Syndrome epidemiology based on gender analyzed that males and females contributed approximately 30 and 45 WHIM Syndrome cases in 2021 in EU-5

  • The WHIM Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage WHIM Syndrome pipeline products will significantly revolutionize the WHIM Syndrome market dynamics.


WHIM Syndrome Overview

WHIM syndrome, which stands for “warts, hypogammaglobulinemia, infections, and myelokathexis,” is a rare primary immunodeficiency disorder characterized by a combination of symptoms including recurrent warts, low levels of certain antibodies in the blood (hypogammaglobulinemia), recurrent bacterial infections, and abnormal retention of mature white blood cells (neutrophils) in the bone marrow (myelokathexis). This condition is caused by mutations in the CXCR4 gene, which is involved in the regulation of white blood cell movement and function. 


Get a Free sample for the WHIM Syndrome Market Report:



WHIM Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.


WHIM Syndrome Epidemiology Segmentation:

The WHIM Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of WHIM Syndrome

  • Prevalent Cases of WHIM Syndrome by severity

  • Gender-specific Prevalence of WHIM Syndrome

  • Diagnosed Cases of Episodic and Chronic WHIM Syndrome


Download the report to understand which factors are driving WHIM Syndrome epidemiology trends @ WHIM Syndrome Epidemiology Forecast


WHIM Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the WHIM Syndrome market or expected to get launched during the study period. The analysis covers WHIM Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the WHIM Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.


WHIM Syndrome Therapies and Key Companies

  • Mavorixafor: X4 Pharmaceuticals

  • Plerixafor: NIAID

  • X4P-001: X4 Pharmaceuticals


Discover more about therapies set to grab major WHIM Syndrome market share @ WHIM Syndrome Treatment Market


WHIM Syndrome Market Strengths

  • Emerging drugs like mavorixafor in late-stage clinical development with strong clinical data for treating neutropenia, lymphopenia, sustained improvements in infections and warts in WHIM syndrome patients

  • Support from regulatory authorities by granting ODD status, Breakthrough Designations, and rare pediatric disease designations to encourage clinical drug development for the treatment of ultra-rare diseases


WHIM Syndrome Market Opportunities

  • There are no disease-specific approved therapies for the treatment of WHIM syndrome  

  • The first product approved for the treatment of WHIM is likely to get a first-mover advantage across the 7MM 

  • The current management of the disease includes only symptomatic treatments and does not affect the underlying cause of the disease CXCR4 mutation 

  • Emerging therapeutic options like Mavorixafor could expand their label to treat severe chronic neutropenia, CVID, and lymphopenia


Scope of the WHIM Syndrome Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key WHIM Syndrome Companies: X4 Pharmaceuticals, NIAID, and others

  • Key WHIM Syndrome Therapies: Mavorixafor, Plerixafor, X4P-001, and others

  • WHIM Syndrome Therapeutic Assessment: WHIM Syndrome current marketed and WHIM Syndrome emerging therapies

  • WHIM Syndrome Market Dynamics: WHIM Syndrome market drivers and WHIM Syndrome market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • WHIM Syndrome Unmet Needs, KOL’s views, Analyst’s views, WHIM Syndrome Market Access and Reimbursement 


To know more about WHIM Syndrome companies working in the treatment market, visit @ WHIM Syndrome Clinical Trials and Therapeutic Assessment


Table of Contents 

1. WHIM Syndrome Market Report Introduction

2. Executive Summary for WHIM Syndrome

3. SWOT analysis of WHIM Syndrome

4. WHIM Syndrome Patient Share (%) Overview at a Glance

5. WHIM Syndrome Market Overview at a Glance

6. WHIM Syndrome Disease Background and Overview

7. WHIM Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of WHIM Syndrome 

9. WHIM Syndrome Current Treatment and Medical Practices

10. WHIM Syndrome Unmet Needs

11. WHIM Syndrome Emerging Therapies

12. WHIM Syndrome Market Outlook

13. Country-Wise WHIM Syndrome Market Analysis (2019–2032)

14. WHIM Syndrome Market Access and Reimbursement of Therapies

15. WHIM Syndrome Market Drivers

16. WHIM Syndrome Market Barriers

17.  WHIM Syndrome Appendix

18. WHIM Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight


About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/